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Keap1 is a highly redox-sensitive member of the BTB-Kelch family that assembles with the Cul3 protein
to form a Cullin–RING E3 ligase complex for the degradation of Nrf2. Oxidative stress disables Keap1,
allowing Nrf2 protein levels to accumulate for the transactivation of critical stress response genes.
Consequently, the Keap1–Nrf2 system is extensively pursued for the development of protein–protein
interaction inhibitors that will stabilize Nrf2 for therapeutic effect in conditions of neurodegeneration,
inﬂammation, and cancer. Here we review current progress toward the structure determination of Keap1
and its protein complexes with Cul3, Nrf2 substrate, and small-molecule antagonists. Together the
available structures establish a rational three-dimensional model to explain the two-site binding of Nrf2
as well as its efﬁcient ubiquitination.
& 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
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Nrf2, encoded by the gene NFE2L2[1], belongs to the Cap’n’Collar
(CNC) subfamily of basic leucine zipper (bZIP) transcription factors,
which in vertebrates comprises NFE2 (nuclear factor erythroid-de-
rived 2) and the NFE2-related factors Nrf1, Nrf2, and Nrf3 [2]. Nrf2
has become the best known family member for its cytoprotective
role in the responses to oxidative and electrophilic stress [3–5]. This
activity is dependent on its transactivation function and itsr Inc. This is an open access article
llock).
ular Medicine, University ofdimerization with members of the small Maf (musculoaponeurotic
ﬁbrosarcoma oncogene homolog) protein family [6]. The Nrf2–Maf
heterodimer is targeted speciﬁcally to genes containing anti-
oxidant-response elements in their regulatory regions, including
many antioxidant and detoxiﬁcation enzymes, ABC transporters,
and other stress response proteins [7,8].
Under normal conditions, the levels of Nrf2 protein are kept
low by the E3 ubiquitin ligase Keap1 (Kelch ECH-associating pro-
tein 1), which ubiquitinates Nrf2 in the cytoplasm and targets it for
degradation by the 26 S proteasome [9–15]. This constitutive de-
gradation of Nrf2 allows for only the basal expression of its target
stress response genes as part of a housekeeping function. How-
ever, under conditions of oxidative stress, or in the presence of
electrophilic xenobiotics, the activity of Keap1 is diminished andunder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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ducible high expression of its target genes. In this manner, Keap1
functions as a critical sensor of cellular stress. Its high redox sen-
sitivity is determined by a number of cysteine residues that are
distributed throughout the Keap1 protein and are vulnerable to
oxidation or to covalent modiﬁcation by electrophiles. Notably,
different reactive chemicals appear to target different cysteines in
Keap1, giving rise to the concept of a “cysteine code” [4,16,17]. Two
residues, Cys273 and Cys288, seem essential for Keap1 to control
Nrf2 under both basal and stress conditions, whereas Cys151 is
primarily required under conditions of stress [18–21]. Other Keap1
residues, including Cys226, Cys434, and Cys613, seem important
for sensing speciﬁc toxins.
As a master regulator of the antioxidant response, the Keap1–
Nrf2 system protects cellular proteins and DNA from oxidative
damage caused by reactive oxygen species and electrophiles. In
addition, it controls transporters critical for cellular detoxiﬁcation.
Consequently, the Keap1–Nrf2 system has emerged as an im-
portant therapeutic target in cancer and neurodegenerative con-
ditions, as well as many autoimmune and inﬂammatory diseases
[2,4,5,16,22]. Critical for such intervention strategies is a deep
understanding of the structure and function of these proteins.
Progress in this respect has relied on the deﬁnition of the domain
architecture of the Keap1 and Nrf2 proteins and the identiﬁcation
of the speciﬁc regions mediating their interactions [23].
The Nrf2 protein in humans is 605 amino acids long and con-
tains seven highly conserved regions known as Nrf2-ECH homol-
ogy (Neh) domains (Fig. 1). Neh1 contains the CNC–bZIP domain,
which mediates heterodimerization with Maf [6]. The Neh2 do-
main contains the two degrons that are speciﬁcally bound by
Keap1. These are commonly known as the DLG and ETGE motifs
after their sequence conservation in the single-letter amino acid
code [24]. Two further redox-independent degrons have since
been described in Neh6 [25]. These motifs are not recognized by
Keap1, but are instead targeted for degradation by the E3 ubiquitin
ligase β-TrCP. This alternative pathway is enhanced by the phos-
phorylation of Nrf2 by glycogen synthase kinase-3β, providing
another mechanism for cellular control of Nrf2 activities [26–28].
The Neh3–5 domains are thought to function in transactivation by
binding to various components of the transcriptional apparatus
[29,30]. Conversely, repression of Nrf2 is conferred by the inter-
actions of Neh7 with the DNA-binding domain of retinoic X re-
ceptor α [31].
Keap1 belongs to the BTB-Kelch family of proteins, which com-
prises some 50 members variously named as Kelch-like 1–42
(KLHL1–42) or Kelch and BTB domain-containing 1–14 (KBTBD1–
14) [32,33]. All of these proteins assemble with Cullin 3 (herein
Cul3) and Rbx1 to form multisubunit Cullin–RING (really interesting
new gene) ligases (CRLs) for protein ubiquitination. Keap1 is clas-
siﬁed as KLHL19 and comprises three domains spanning some 611
amino acids (Fig. 1). The N-terminal BTB domain is named after the
Drosophila proteins Broad complex, Tramtrack, and Bric à brac, in
which it was ﬁrst identiﬁed [34]. The BTB domain mediates the
homodimerization of Keap1 and contributes additionally to its in-
teraction with Cul3 [35]. A further Cul3 interaction is provided byFig. 1. Domain architecture of the Keap1 and Nrf2 proteins. Domain boundaries
and residue numbers are shown for the human proteins.the 3-box motif, which forms the proximal part of the central in-
tervening region (IVR domain) [32]. The C-terminal Kelch domain is
required for substrate capture and can bind separately to the ETGE
[36,37] or DLG [38,39] motifs of Nrf2.
To date there are no available high-resolution structures de-
scribing either of the full-length Keap1 or Nrf2 proteins. None-
theless, a number of crystal structures featuring Keap1, or its BTB-
Kelch family homologs, have revealed the molecular mechanisms
determining its interactions with Nrf2 substrate or Cul3 protein, as
well as the action of chemical inhibitors that stabilize Nrf2 for
therapeutic gain.2. Structural basis of Nrf2 binding to the Kelch domain of
Keap1
Nuclear magnetic resonance spectroscopy has shown the Neh2
region of Nrf2 to be intrinsically disordered [24], but capable of
binding to the full-length Keap1 protein at low nanomolar con-
centrations (KD value 5 nM) [24,40]. This binding was replicated
by a 16-residue peptide (AFFAQLQLDEETGEFL) incorporating ami-
no acids 69–84 of Nrf2, which ﬂank the conserved ETGE motif [24].
Subsequently, the molecular nature of this interaction was cap-
tured by two high-resolution crystal structures. The structure of
the same 16-residue Nrf2 peptide was solved at 1.5- Å resolution
in complex with the Kelch domain of human Keap1 [36]. A further
structure was solved independently at 1.7- Å resolution compris-
ing the equivalent mouse Kelch domain and a shorter peptide
spanning residues 76–84 of Nrf2 [37]. Additionally, crystal struc-
tures have been reported for the human and mouse Kelch domains
in the absence of ligand [37,41,42].
Overall, the Kelch domain contains six Kelch repeats that fold
into a six-bladed β-propeller structure [42]. Each blade (I–VI)
comprises a four-stranded antiparallel β-sheet (β strands A–D), in
which the shorter βA strands form the central core. The ﬁnal βA
strand from the C-terminal region (CTR) closes the propeller by
completing blade I. The Kelch repeats are notably diverse in se-
quence, allowing for substrate selectivity, but contain a limited
number of conserved positions that maintain the overall fold
[32,43]. These include a double-glycine repeat (DGR) that termi-
nates the βB strand as well as individual tyrosine (βC) and tryp-
tophan (βD) residues that mediate hydrophobic packing between
blades. Based on this consensus, the Kelch domain has also been
described as the DGR or DC (DGR and CTR) domain [37,43,44].
The substrate binding surface lies on one face of the Kelch
domain, where a shallow pocket is created by the long loops that
connect β-strands D and A (DA loop) as well as β-strands B and C
(BC loop). The bound ETGE peptide of Nrf2 adopts a β-turn con-
formation that inserts into this pocket to establish a buried surface
area of 420 Å2 (Fig. 2A) [36,37]. Speciﬁc electrostatic interactions
are made by both glutamate residues in the ETGE motif. Glu79 in
Nrf2 forms hydrogen bonds with Keap1 residues Arg415, Arg483,
and Ser508, whereas Glu82 hydrogen bonds with Keap1 residues
Ser363, Asn382, and Arg380. Further electrostatic contacts medi-
ated through water or the peptide backbone are supplemented by
additional van der Waals interactions.
The conserved DLG motif in the Neh2 region of Nrf2 was
identiﬁed as a second independent binding site with 100-fold
weaker afﬁnity for Keap1 [24]. Its complex with the Kelch domain
of mouse Keap1 was solved initially at 1.9- Å resolution using a
peptide spanning amino acids 22–36 of Nrf2 [38]. Whereas elec-
tron density was observed only for Nrf2 residues 24–29, the
structure revealed a β-turn conformation similar to that of the
ETGE motif, as well as a similar peptide interaction mode. A fur-
ther costructure was subsequently solved at 1.6- Å resolution using
a larger DLG peptide incorporating Nrf2 residues 17–51 (Fig. 2B)
Fig. 2. Binding of Nrf2 to Keap1. (A) Selected side-chain interactions are shown in the complex of human Keap1 and the Nrf2 ETGE motif (PDB 2FLU). Kelch domain positions
with known somatic cancer mutations (G364C and G430C) are shown in orange; other Keap1 and Nrf2 interface residues are shown in gray and green, respectively.
(B) Selected side-chain interactions in the DLG motif complex with mouse Keap1 (PDB 3WN7). DLG peptide residues are colored yellow; Keap1 residues are colored as in (A).
(C) Comparison of the binding of the ETGE (green) and DLG (yellow) peptides. Colored areas on the Keap1 surface indicate the main interacting residues (blue, basic; red,
polar; purple, hydrophobic). (D) Structural basis for Keap1 inhibition by small molecules targeting the Kelch domain. The electrostatic potential of the protein surface reveals
a basic patch around the Nrf2 binding site. A bound small-molecule inhibitor is shown from PDB 4L7B (chain B) [70].
P. Canning et al. / Free Radical Biology and Medicine 88 (2015) 101–107 103[39]. Importantly, this structure revealed a more extended and
distinct binding interface, as well as an altered Nrf2 peptide con-
formation consisting of an N-terminal helix (Leu19–Arg25) and
two short 310 helices (Ile28 to Leu30 and Arg34 to Phe37). In this
revised structure, the DLG motif residues Asp29–Leu30–Gly31 are
located similar to the ETGE motif residues Glu79–Thr80–Gly81.
Comparison of the DLG and ETGE peptide complexes shows that
they insert in a manner similar to the bottom of the Kelch domain
pocket, but that they deviate at their N-terminus owing to the he-
lical conformation of the DLG peptide motif (Fig. 2C). Thermo-
dynamic analyses using isothermal titration calorimetry showed
that the Keap1–ETGE interaction was enthalpy-driven, consistent
with the large number of electrostatic interactions observed. By
contrast, the weaker Keap1–DLG interaction was characterized by a
reduced enthalpy, but a small favorable entropy [39]. Differences
were also observed in the binding kinetics. The ETGE peptide ex-
hibited a slow on and slow off rate yielding a high-afﬁnity inter-
action, whereas the weaker binding DLG peptide showed fast ki-
netics for both its association and its dissociation [39].
These differences are thought to be important for ﬁne-tuning
regulation of the stress response [45]. The separate DLG and ETGE
motifs allow a single Nrf2 molecule to bind to the two Kelch do-
mains present in the Keap1 dimer. A hinge and latch mechanism
has been proposed in which the high-afﬁnity ETGE motif acts as a
hinge anchored to the ﬁrst Kelch domain, whereas the weaker DLG
motif is engaged as the latch to maintain minimal housekeeping
expression levels of the Nrf2 protein [45]. A model for the fullKeap1 E3 ligase complex is discussed further below. Its proper
assembly is thought to be important to correctly position the Neh2
domain for ubiquitination and may be disrupted under conditions
of cellular stress by modiﬁcations to the reactive cysteine residues
in Keap1 [24,38,44].
The Kelch domain structures also help to explain the effects of
somatic cancer mutations identiﬁed in Keap1 (Figs. 2A and 2B), as
well as those in Nrf2, which cluster to the DLG and ETGE motifs
[37,39,46]. These mutations destabilize the Keap1–Nrf2 interac-
tion leading to Nrf2 protein stabilization and induced transcrip-
tional responses that protect cancer cells from environmental
stresses, including the potential toxicity of cancer drugs or radia-
tion therapy [47–49].3. Structural basis of Keap1 dimerization
The BTB domain is a protein–protein interaction domain found
throughout eukaryotes as well as in the poxvirus zinc ﬁnger (POZ)
protein family and is consequently sometimes referred to as the
BTB/POZ domain [34,50–52]. Over 350 different BTB-containing
proteins are identiﬁed in humans, of which the majority are found
in combination with other domains. The BTB fold was ﬁrst deﬁned
by the structure of the promyelocytic leukemia zinc ﬁnger (PLZF)
protein, which belongs to the human BTB-ZF class of transcrip-
tional repressors [53].
The structure of the BTB domain of Keap1 was reported in 2014
P. Canning et al. / Free Radical Biology and Medicine 88 (2015) 101–107104and shows a fold similar to the PLZF domain despite its low se-
quence identity and divergent cellular function [35]. Both struc-
tures show a tightly intertwined homodimer, with the individual
domains related by a crystallographic twofold axis (Fig. 3A). The
shared fold comprises a three-stranded β-sheet ﬂanked by six α-
helices. Structural elements across the fold contribute to the dimer
interface, providing a signiﬁcant buried surface area in Keap1 of
2001 Å2. Notable among these are the long α1 helix and the
N-terminal β1 strand, which forms a domain-swapped antiparallel
β-sheet with the β5 strand of the other bound subunit. Some
members of the BTB-Kelch family have been reported to hetero-
dimerize, such as the KLHL9 and KLHL13 protein pair [54]. How-
ever, these two proteins are highly conserved in their primary
sequences. The Keap1 protein has no such closely conserved
homologs within this family and its BTB domain is thought to exist
as an obligate homodimer.4. Structural basis of Keap1 assembly with Cul3
The E3 ligase activity of Keap1 requires its assembly with Cul3
to become part of a larger CRL3 complex [13,55]. Whereas no
structures currently exist for this complex, the structure of the
relevant Cul3 N-terminal domain has been solved in complexes
with other homologous BTB-Kelch family members, including
KLHL3 and KLHL11 [32,56]. The Cul3 protein forms a stalk-like
scaffold that binds and orients the substrate-binding E3 subunit at
its N-terminus and a RING protein at its C-terminus [57–59].
The Cul3 N-terminal domain contains three Cullin repeats, each
folded as a ﬁve-helix bundle, as well as an N-terminal extension ofFig. 3. BTB dimerization and Cul3 binding. (A) Ribbon representation of the Keap1 BTB d
CDDO (PDB 4CXT), which forms a covalent bond to the side chain of Cys151. (B) Model of
4AP2). Cul3 is shown in red, whereas the BTB, 3-box, and IVR domains are colored as sho
between the residues of the Cul3 N-terminal extension and the 3-box of KLHL11.some 24 amino acids [32]. Each subunit in the BTB dimer binds
one Cul3 molecule yielding a large heterotetramer with a twofold
symmetry axis across the BTB dimer. The BTB domain is bound
primarily by the H2 and H5 helices of the ﬁrst Cullin repeat,
whereas the Cul3 N-terminal extension inserts into an adjacent
hydrophobic groove formed by the proximal 3-box motif (Fig. 3B)
[32]. The 3-box is a conserved C-terminal extension of the BTB
domain found in most Cul3-dependent E3 ligases, including the
BTB-Kelch proteins and the MATH-BTB family [58]. Structures in-
cluding this domain have been solved for the MATH-BTB protein
SPOP [58,60], as well as the BTB-Kelch proteins KLHL3, KLHL11,
Gigaxonin (or KLHL16), and KBTBD4 [32,56,58]. These show the
3-box motif to consist of two helices (α7 and α8) that pack in an
antiparallel four-helix bundle conﬁguration with the two C-term-
inal helices of the BTB domain (α5 and α6).
The 3-box motif connects the BTB domain to the central por-
tion of the Keap1 protein known either as the IVR domain or the
BACK (BTB and C-terminal Kelch) domain [61]. This region was
ﬁrst fully characterized in the KLHL11 crystal structure and con-
tains a further six helices (α9–α14) that pack perpendicular to the
3-box (Fig. 3B) [32]. Bioinformatic analyses suggest that this region
is structurally conserved in Keap1 [32,56,61].5. Model for Nrf2 degradation by Keap1
A model of the full-length Keap1 homodimer has been ob-
tained at low resolution by single-particle electron microscopy
[44]. Reconstruction at 24-Å resolution has revealed two large
spheres attached by short linker arms to the sides of a smallimer (PDB 4CXI). The inset shows the binding mode of the antagonist bardoxolone/
the Cul3 interface, based on the crystal structure of the KLHL11–Cul3 complex (PDB
wn in Fig. 1. The second BTB subunit is colored gray. The inset shows the interaction
P. Canning et al. / Free Radical Biology and Medicine 88 (2015) 101–107 105forked-stem structure. The stem matches the shape and size of the
BTB dimer, whereas each sphere would appear to incorporate the
Kelch domain positioned atop the IVR domain [44]. This structure
provides support for the two-site binding model of Nrf2 in which
the Neh2 domain spans the gap between the two Kelch domains,
which separately engage the ETGE and DLG motifs. The region
between these two degrons has predicted helical structure and
contains seven lysine residues as potential ubiquitin-acceptor
sites, suggesting that the dimeric Keap1 structure is required to
immobilize this Nrf2 segment for efﬁcient ubiquitination.
A more complete model of the full CRL3 complex (Fig. 4) has
been proposed based on the related KLHL11–Cul3 structure [32]
and other known Cul1 [59] and Cul5 [62] complex structures. Such
modeling is possible owing to the core elements of the BTB fold
that are conserved in the structures of the Cul1-adaptor protein
Skp1 [63] and the Cul2/5-adaptor ElonginC [64–67]. These adap-
tors bind to different E3 ligases containing F-box and SOCS box
motifs, which are functionally analogous to the 3-box, although
distinct in structure. The ﬁnal model includes the Cul3 C-terminal
domain as well as the bound RING domain protein Rbx1, which
recruits the charged E2-ubiquitin moiety. Neddylation (the cova-
lent attachment of the small protein Nedd8) to a speciﬁc lysine in
the Cul3 C-terminal domain is thought to modulate the con-
formation of this complex allowing the closest association of the
substrate and E2-ubiquitin [62]. Signiﬁcantly, the model places the
E2-ubiquitin subunits centrally and above the Neh2 domain,
where they seem poised to participate in Nrf2 ubiquitination
(Fig. 4). The precise mechanism of polyubiquitination remains to
be elucidated.6. Structural insights into Keap1 inhibition
Chemical inducers of Nrf2 that block Keap1 function have pro-
ven an effective mechanism to exploit the antioxidant response in
the ﬁght against human disease. Indeed, the Nrf2 inducer BG-12, a
formulation including dimethyl fumarate, was recently approved
for the treatment of relapsed multiple sclerosis [68]. The majority of
antagonists are electrophiles that covalently modify the free cy-
steines in the Keap1 protein. The mechanism of action of one such
molecule, the triterpenoid bardoxolone (also known as CDDO), has
been revealed by a cocrystal structure with the BTB domain of
Keap1 [35]. This molecule binds covalently to Keap1 Cys151 and
nestles in a shallow groove between the α4 and the α5 helices
(Fig. 3A). Although the interaction induces subtle rearrangements in
the local vicinity of Keap1, the bulk of bardoxolone is thought toFig. 4. Model of the fully assembled CRL3 complex. (A) Structural model assembled as
between the bound DLG and ETGE sites. (B) Schematic illustration of the complex showinhibit Cul3 binding by blocking the adjacent hydrophobic groove of
the 3-box [35]. This loss of binding prevents the recruitment of E2-
ubiquitin and abrogates Nrf2 ubiquitination.
Other electrophiles are expected to bind to Cys273 and Cys288
in the IVR domain [17]. These molecules are predicted to distort the
IVR domain fold. Any such perturbation could alter the stable po-
sitioning of the associated BTB and Kelch domains and so induce an
improper geometry for ubiquitination or, alternatively, affect pro-
tein–protein interactions in the Cullin–RING ligase complex
[32,40,56]. Severe perturbations might be expected to break the
tethering of Nrf2, consistent with the dissociation observed in
studies of the mouse Keap1 protein [18]. However, ITC experiments
using chemical modiﬁers of human Keap1 have suggested that the
overall afﬁnity for binding of the Neh2 domain is unchanged [40].
Thus, it is likely that the integrity of the Kelch domain fold is not
affected. Without productive ubiquitination, the stable association
of Nrf2 with Keap1 is expected to block further substrate binding
and turnover, leading to the accumulation of newly synthesized
Nrf2 and the consequent induction of the antioxidant response [69].
However, a precise understanding of the consequences of these
electrophiles awaits additional structural studies.
More recently, a number of cocrystal structures have been re-
ported for small-molecule inhibitors that target the Kelch domain
noncovalently and compete directly for binding with the Nrf2
peptide [70,71]. These molecules occupy the same shallow pocket
in Keap1 used by the ETGE and DLG motifs (Fig. 2D). This pocket
has a markedly electropositive surface potential and is rich in basic
arginine side chains. As a consequence, the most potent binders
contain acidic groups that are challenging for cell permeability.
Nonetheless, the ability of small molecules to target the BTB, the
IVR, or the Kelch domain presents a welcome toolbox for biologists
and a diverse set of therapeutic strategies for evaluation in pre-
clinical and clinical studies [23].7. Conclusions
A combination of biochemical and structural studies has yiel-
ded remarkable insights into the molecular mechanisms control-
ling the cellular response to oxidative and electrophilic stress.
Importantly, the structural models are consistent with the pro-
posed two-site hinge and latch model for Nrf2 capture and reveal
sensible spatial arrangements for its subsequent ubiquitination.
Their construction is particularly enabled by the modular nature of
the Cullin–RING ligases, which allows different structures to be
assembled together for an understanding of the entire complex.previously described [32]. A predicted helix in the Neh2 region of Nrf2 is modeled
n in (A).
P. Canning et al. / Free Radical Biology and Medicine 88 (2015) 101–107106However, the lack of a high-resolution full-length Keap1 structure
currently limits our knowledge in several respects. Progress here is
perhaps hindered by the short linker that connects the IVR and
Kelch domains. For example, the structure of the MATH-BTB pro-
tein SPOP shows an analogous linker that is highly ﬂexible leading
to asymmetry in the dimeric protein, as well as the E3-substrate
complex [58]. Thus, it remains an open question whether rigidity
or partial ﬂexibility is optimal for Keap1 activity. Uncertainty about
the position of the Kelch domain, as well as the undetermined
structure of the Keap1 IVR domain, also means that there is still
much to learn about the cysteine code.
Overall, the lessons learned from the Keap1–Nrf2 system pro-
vide a prototype model for our understanding of the entire BTB-
Kelch family. Structural studies across this family are less advanced,
but already reveal a diversity in the Kelch domain substrate pocket,
as well as alternative peptide binding conformations and interfaces
[32,72,73]. These data support the general concept of targeting the
Kelch domain with small molecules to selectively interfere with
substrate recruitment, whereas the cysteine-rich sensor mechanism
currently appears unique to Keap1.Acknowledgments
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